GSK unit, ex-CEO didn't commit fraud, jury finds; FDA blesses handful of Aciphex generics;

@FiercePharma: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Article | Follow @FiercePharma

@EricPFierce: AstraZeneca thinks there is no place like home for new Zoladex plant. Story | Follow @EricPFierce

@CarlyHFierce: Rare-disease co. ViroPharma finally snatched up after lots of speculation--Shire gets it for $4.2B. Release | Follow @CarlyHFierce

> A federal jury determined that GlaxoSmithKline ($GSK) subsidiary Stiefel Laboratories and its former CEO, Charles Stiefel, didn't committ securities fraud as the company prepared for sale. Report

> The FDA approved the first generic versions of Eisai's Aciphex, a proton-pump inhibitor treatment for heartburn and acid reflux, from a variety of drugmakers, including Dr. Reddy's and Mylan ($MYL). Report

> South Africa's state-owned Public Investment Corporation, which rejected the proposed buyout of Adcock Ingram by Chile's CFR Pharmaceutical, apparently is worried about foreign ownership of a key domestic drugmaker. Report

> U.S. investigators are looking into the widespread theft and black-market sale of malaria drugs donated for use in Africa. Report (sub. req.)

> Sagent Pharma ($SGNT) launched its version of the injectable drug doxorubicin, used to treat a variety of cancers. Report

> Horizon Pharma ($HZNP) and Mundipharma inked a deal to commercialize the rheumatoid arthritis treatment Lodotra in the Middle East and Africa. Report (sub. req.)

Medical Device News

@FierceMedDev: Solta's aesthetic device sales sag, prompting company to explore selling itself. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Don't over-promise on what your medical device can deliver. Via BBJ. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Chinese investors pursue groundbreaking med tech from Canada's MDI. Article | Follow @MichaelGFierce

> Report: Boston Scientific leads $20M round for Israeli devicemaker. More

> Rise in reported surgical robot problems could spur training surge. Item

> Hologic tanks as $1.1B charge wipes profits. News

Biotech News

@FierceBiotech: GlaxoSmithKline loses its first big PhIII bet on heart drug darapladib. News | Follow @FierceBiotech

@JohnCFierce: Sarepta down 58%--about $700M in market cap vanished. | Follow @JohnCFierce

@DamianFierce: Dendreon slashing about 200 more jobs as Provenge sales slide and buyer interest comes up short. More | Follow @DamianFierce

@EmilyMFierce: New drug target identified for glioblastoma. More | Follow @EmilyMFierce

> Vanda soars after FDA reviewer urges OK for sleep disorder drug. Report

> PsiOxus racks up promising PhII results for cancer-wasting drug. More

Pharma Manufacturing News

> AstraZeneca stays in England with $190 million plant. More

> J&J, Amazon fight shows supply-chain weakness in online sales. Story

> Actavis to close NC plant, trim 310 jobs. News

> Daiichi Sankyo says it was burned in Ranbaxy buyout. Article

> Alexion recalls more Soliris. Report

> More than 27M pharma units recalled in Q3. Item

Biotech Research News

> Report proposes revamping Alzheimer's R&D. More

> Japanese fund awards $5.7M in infectious disease vaccine work. Story

> Government shutdown effects on biomedical research outlined. Report

> MacroGenics to receive $9M from Boehringer Ingelheim in preclinical antibody pact. Item

> Compound mimicking gene deletion stops tissue scarring in mice. News

> New drug target identified for glioblastoma. Article

And Finally... International relief agencies, including the healthcare group Doctors Without Borders, are collecting donations to help the victims of Typhoon Haiyan in the Philippines. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.